Malignant Ovarian Endometrioid Tumor — Trials

Malignant Ovarian Endometrioid Tumor — Trials · CancerIndex

Clinical trials

Registered studies

75 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 31
Recruiting: 13
Ph III recruiting: 4
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05226507	A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer	terminated	Phase 1	45	Nuvectis Pharma, Inc.INDUSTRY	2	Aug 6, 2026	clinicaltrials
NCT03924245	Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers	terminated	Phase 1	3	Vanderbilt-Ingram Cancer CenterOTHER	1	Apr 4, 2022	clinicaltrials